Friday, November 17, 2017 2:06:07 AM
1. as discussed that they broadened the possible application of "exon 20 insertions" in other cancer types. But investors don't know how much meat there is. So any rise based on this is just greed and any investor that buys because of the words of R.S. has no excuse if he gets burned.
2. breakthrough for poziotinib is just around the corner - the market is pricing it in and maybe now or in the future pricing it above the real value ..
3. They mentioned for the first time that they will partner their assets in Japan and Europe - this is one thing the market always reacts on, because of the cash inflow and the prospect that there won't be any dilutions any more (= break even on the horizon is always the strongest price driver in biotech)
4. The IBB / NBI and the overall market is bottening. All other stocks in my portfolio did a good jump, too.
So number 3 and 4 have the greatest weight for me.
Recent SPPI News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 11/09/2023 10:00:17 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 09/28/2023 04:15:27 AM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 09/26/2023 09:23:08 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM